- Zacks•2 hours ago
Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of cardiovascular (CV) risk reduction data from the EMPA-REG OUTCOME study on its type II diabetes drug Jardiance's (SGLT-2 inhibitor) label.
- Benzinga•20 hours ago
“In a research lab, one of the most critical parts of scientific research is what we call sample preparation. It is absolutely critical that you are as good as you can be when you’re preparing the sample ...
LLY : Summary for Eli Lilly and Company Common St - Yahoo Finance
Eli Lilly and Company (LLY)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Bid||67.53 x 200|
|Ask||67.55 x 200|
|Day's Range||67.13 - 67.72|
|52 Week Range||64.18 - 87.67|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||29.40|
|Dividend & Yield||2.04 (3.01%)|
|1y Target Est||N/A|